Search

Your search keyword '"Sparaventi, Giovanni"' showing total 7 results
Start Over Author "Sparaventi, Giovanni" Publication Type Magazines
7 results on '"Sparaventi, Giovanni"'

1. Malignant Melanoma of the Glans Penis in a Chronic Myeloid Leukemia Patient after Busulfan Therapy

Author

Sparaventi, Giovanni, Manna, Annunziata, Muretto, Pietro, Pazzaglia, Carlo, Palazzi, Mariangela, and Porcellini, Adolfo

Abstract

There are many case reports of secondary neoplasms occurring after treatment with alkylating agents. A case of malignant melanoma of the glans penis in a chronic myeloid leukemia (CML) Ph'-positive patient after 13 years on busulfan treatment is described. Since neither impairment of immune status nor increased incidence of secondary neoplasm have hitherto been reported in CML, the suggestion that busulfan has a carcinogenetic effect is discussed.

Published
1987
Full Text
View/download PDF

2. Tosedostat Plus Low Dose Cytarabine Induces a High Rate of Responses That Can be Predicted By Genetic Profiling in Elderly AML

Author

Visani, Giuseppe, Loscocco, Federica, Fuligni, Fabio, Zuffa, Eliana, Sensi, Alberto, Zaccaria, Alfonso, Musuraca, Gerardo, Giannini, Barbara, Lucchesi, Alessandro, Fabbri, Francesca, Mianulli, Anna Maria, Tosi, Patrizia, Tonelli, Michela, Candoni, Anna, Fanin, Renato, Sparaventi, Giovanni, Gobbi, Marco, Clavio, Marino, Rocchi, Marco, Piccaluga, Pier Paolo, and Isidori, Alessandro

Abstract

Fanin: Novartis Farma: Speakers Bureau.

Published
2015
Full Text
View/download PDF

3. Tosedostat Plus Low Dose Cytarabine Induces a High Rate of Responses That Can be Predicted By Genetic Profiling in Elderly AML

Author

Visani, Giuseppe, Loscocco, Federica, Fuligni, Fabio, Zuffa, Eliana, Sensi, Alberto, Zaccaria, Alfonso, Musuraca, Gerardo, Giannini, Barbara, Lucchesi, Alessandro, Fabbri, Francesca, Mianulli, Anna Maria, Tosi, Patrizia, Tonelli, Michela, Candoni, Anna, Fanin, Renato, Sparaventi, Giovanni, Gobbi, Marco, Clavio, Marino, Rocchi, Marco, Piccaluga, Pier Paolo, and Isidori, Alessandro

Abstract

Background:Older (age ≥60 years) patients with acute myeloid leukemia (AML) have poor outcomes and intensive induction chemotherapy is frequently unsuitable. Thus, new safe and effective therapies are urgently needed. Tosedostat, a new, orally bioavailable inhibitor of members of the M1 and M17 classes of aminopeptidases, was proven to be effective in both de novo and relapsed AML. We hypothesize that the addition of tosedostat to cytarabine may improve the response rate and remission duration over what is expected with chemotherapy or tosedostat alone.

Published
2015
Full Text
View/download PDF

4. Low-Dose Lenalidomide Plus Low Dose Cytarabine Induce Complete Remission That Can Be Predicted By Genetic Profiling In Very Elderly Acute Myeloid Leukemia Patients

Author

Visani, Giuseppe, Di Raimondo, Francesco, Ferrara, Felicetto, Loscocco, Federica, Piccaluga, Pier Paolo, Fuligni, Fabio, Gazzola, Anna, Rossi, Maura, Laginestra, Antonella, Caraci, Maria Rita, Riccardi, Cira, Visani, Axel, Barulli, Sara, Guiducci, Barbara, Ricciardi, Teresa, Sparaventi, Giovanni, Rocchi, Marco, and Isidori, Alessandro

Abstract

Celgene is acknowledged for providing Lenalidomide for the patients. The study was supported in part by AIL Pesaro Onlus.No relevant conflicts of interest to declare.

Published
2013
Full Text
View/download PDF

5. Low-Dose Lenalidomide Plus Low Dose Cytarabine Induce Complete Remission That Can Be Predicted By Genetic Profiling In Very Elderly Acute Myeloid Leukemia Patients

Author

Visani, Giuseppe, Di Raimondo, Francesco, Ferrara, Felicetto, Loscocco, Federica, Piccaluga, Pier Paolo, Fuligni, Fabio, Gazzola, Anna, Rossi, Maura, Laginestra, Antonella, Caraci, Maria Rita, Riccardi, Cira, Visani, Axel, Barulli, Sara, Guiducci, Barbara, Ricciardi, Teresa, Sparaventi, Giovanni, Rocchi, Marco, and Isidori, Alessandro

Abstract

Outcome for older patients with acute myeloid leukemia (AML) is extremely poor. Intensive induction chemotherapy is often unsuitable. In this phase II study we tested, for the first time, the efficacy of a novel combination therapy with low-dose lenalidomide plus low-dose cytarabine. Further, based on the hypothesis that genetic features might influence treatment response, we aimed at identifying a possible biomarker by studying the global gene expression profiles (GEP).

Published
2013
Full Text
View/download PDF

6. LOW-DOSE LENALIDOMIDE COUPLED with LOW-DOSE Cytarabine INDUCES COMPLETE REMISSION of Elderly ACUTE Myeloid LEUKEMIA PATIENTS with Unfavorable Citogenetics: PRELIMINARY RESULTS of A PHASE II STUDY,

Author

Visani, Giuseppe, Ferrara, Felicetto, Raimondo, Francesco Di, Caraci, Maria Rita, Izzo, Tiziana, Barulli, Sara, Guiducci, Barbara, Loscocco, Federica, Ricciardi, Teresa, Sparaventi, Giovanni, and Isidori, Alessandro

Abstract

Celgene is acknowledged for providing Lenalidomide for the patients. The study was supported in part by AIL Pesaro Onlus.The Authors declare no competing financial interests.Di Raimondo: celgene: Honoraria.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results